| Title： | Expert Consensus on Rational Use of Drugs in Nebulized Inhalation Therapy (2024 Edition) |
| Edition： | Updated |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Healthcare professionals from various disciplines involved in the application of nebulized therapy, such as doctors, pharmacists and nurses in respiratory departments, emergency departments, pediatrics, geriatrics, etc. |
| Evidence classification method： | Level A (high-quality evidence): consistent results obtained from high-quality studies provided by directly related high-quality guidelines, high-quality studies evaluated through the Cochrane system and high-quality randomized controlled trials or observational studies; And it is required that the evidence body contains sufficient research quantity and population characteristics, with a large sample size, and provide accurate effect estimates. At the same time, no other limitations were found. Level B (medium quality evidence): There are design limitations in studies provided by directly related high-quality guidelines, studies evaluated through the Cochrane system, randomized controlled trials or observational studies, that may affect the estimation of effects; Or some research results show inconsistency; Or although the estimated value of the effect shows clinical significance, the evidence body contains insufficient research quantity and population characteristics, and the sample size is limited. At the same time, no other limitations were found. Level C (low-quality evidence): In studies provided by directly related high-quality guidelines, studies evaluated through the Cochrane system, randomized controlled trials or observational studies, the vast majority have serious design limitations that can affect the estimated effects; Or the results of various studies show significant inconsistency; OR the number of studies and population characteristics included in the evidence body is small, the sample size is small, and the estimated effects are inaccurate; Or the evidence has indirectness or other serious limitations. Expert opinion: There is insufficient research evidence to support it. The guidelines working group reached a consensus based on clinical experience and professional knowledge but did not directly provide expert evidence. |
| Development unit： | Chinese Society of Clinical Pharmacy |
| Registration time: | 2024-02-01 |
| Registration number： | PREPARE-2024CN234 |
| Purpose of the guideline: | Nebulized inhalation therapy is one of the important treatments for respiratory diseases. However, in China, due to insufficient understanding of nebulized inhalation therapy and drugs, there are many irrational use phenomena in clinical applications. Although the "Expert Consensus on the Rational Use of Drugs in Nebulized Inhalation Therapy" (2019 Edition) has answered and responded to many questions, with the launch of new drugs and devices in recent years, as well as changes in the epidemiology of respiratory diseases, new problems have arisen with the application of nebulized inhalation therapy. This consensus update will combine epidemiological changes and incorporate the latest evidence-based evidence, drugs and devices, etc., to provide the latest basis for standardizing the rational application of nebulized inhalation therapy. |
